JP6026424B2 - 治療薬送達のための生物浸食性ケイ素ベースのデバイス - Google Patents

治療薬送達のための生物浸食性ケイ素ベースのデバイス Download PDF

Info

Publication number
JP6026424B2
JP6026424B2 JP2013536924A JP2013536924A JP6026424B2 JP 6026424 B2 JP6026424 B2 JP 6026424B2 JP 2013536924 A JP2013536924 A JP 2013536924A JP 2013536924 A JP2013536924 A JP 2013536924A JP 6026424 B2 JP6026424 B2 JP 6026424B2
Authority
JP
Japan
Prior art keywords
carrier material
therapeutic agent
pores
pore size
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013536924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541562A (ja
JP2013541562A5 (https=
Inventor
アシュトン，ポール
カナム，リー，ティー．
バーネット，クリスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Psivida US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida US Inc filed Critical Psivida US Inc
Publication of JP2013541562A publication Critical patent/JP2013541562A/ja
Publication of JP2013541562A5 publication Critical patent/JP2013541562A5/ja
Application granted granted Critical
Publication of JP6026424B2 publication Critical patent/JP6026424B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013536924A 2010-11-01 2011-11-01 治療薬送達のための生物浸食性ケイ素ベースのデバイス Expired - Fee Related JP6026424B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40893410P 2010-11-01 2010-11-01
US61/408,934 2010-11-01
US201161470299P 2011-03-31 2011-03-31
US61/470,299 2011-03-31
PCT/US2011/058774 WO2012061377A1 (en) 2010-11-01 2011-11-01 Bioerodible silicon-based devices for delivery of therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016019772A Division JP6189460B2 (ja) 2010-11-01 2016-02-04 治療薬送達のための生物浸食性ケイ素ベースのデバイス

Publications (3)

Publication Number Publication Date
JP2013541562A JP2013541562A (ja) 2013-11-14
JP2013541562A5 JP2013541562A5 (https=) 2015-01-08
JP6026424B2 true JP6026424B2 (ja) 2016-11-16

Family

ID=46024803

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013536924A Expired - Fee Related JP6026424B2 (ja) 2010-11-01 2011-11-01 治療薬送達のための生物浸食性ケイ素ベースのデバイス
JP2016019772A Expired - Fee Related JP6189460B2 (ja) 2010-11-01 2016-02-04 治療薬送達のための生物浸食性ケイ素ベースのデバイス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016019772A Expired - Fee Related JP6189460B2 (ja) 2010-11-01 2016-02-04 治療薬送達のための生物浸食性ケイ素ベースのデバイス

Country Status (11)

Country Link
US (3) US9333173B2 (https=)
EP (1) EP2635255B1 (https=)
JP (2) JP6026424B2 (https=)
CN (4) CN103282020B (https=)
AU (2) AU2011323524B2 (https=)
CA (1) CA2816576C (https=)
HK (3) HK1210048A1 (https=)
IN (1) IN2013MN00758A (https=)
RU (1) RU2640918C2 (https=)
TW (1) TWI615150B (https=)
WO (1) WO2012061377A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US9023896B2 (en) 2009-05-04 2015-05-05 Psivida Us, Inc. Porous silicon drug-eluting particles
CN103282020B (zh) 2010-11-01 2016-10-26 普西维达公司 用于递送治疗剂的可生物侵蚀的硅基装置
US20140309610A1 (en) * 2013-03-12 2014-10-16 Psivida Corp. Drug Delivery Device Comprising Silicon-Based Carrier Particles
WO2014165108A1 (en) * 2013-03-12 2014-10-09 Psivida Us, Inc. Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
WO2014151381A1 (en) * 2013-03-15 2014-09-25 Psivida Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents
US20160075776A1 (en) * 2014-09-16 2016-03-17 Paul Ashton Compositions and Methods for Controlled Release of Agents
JP6883257B2 (ja) * 2017-05-16 2021-06-09 株式会社豊田中央研究所 還元反応用固体触媒
WO2019246141A1 (en) 2018-06-19 2019-12-26 Cella Therapeutics, Llc DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE
EP3810082A1 (en) 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
EP4049652A1 (en) * 2021-02-26 2022-08-31 Nano Targeting & Therapy Biopharma Inc. Method for delivering an agent to posterior segment of an eye and uses thereof
TWI803092B (zh) * 2021-04-01 2023-05-21 逢甲大學 具負載與釋放活性成分的奈米粒子、其製造方法與眼用裝置之應用
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117281687A (zh) * 2023-09-22 2023-12-26 海思盖德(苏州)生物医学科技有限公司 一种眼用引流管及其制备方法与应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832458A (en) 1971-12-06 1974-08-27 River C Foundation Hydrophilic silicone composition and method
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US3919723A (en) 1974-05-20 1975-11-18 Friedrichsfeld Gmbh Bone shaft or bone joint prosthesis and process
US3919060A (en) 1974-06-14 1975-11-11 Ibm Method of fabricating semiconductor device embodying dielectric isolation
DE3214667C2 (de) 1982-04-21 1985-07-18 Akzo Gmbh, 5600 Wuppertal Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen
JPS59101145A (ja) 1982-11-30 1984-06-11 日本特殊陶業株式会社 薬液含浸多孔質セラミツクス
JPS59131346A (ja) 1983-01-17 1984-07-28 日本特殊陶業株式会社 薬液含浸多孔質セラミツクスの製造法
DE3423667A1 (de) 1984-05-08 1985-11-28 Rüdiger Dipl.-Ing. 5204 Lohmar Scheunemann Implantat fuer knochen- und zahnwurzelersatz mit spezieller uebergangsstruktur zwischen knochen und implantatkern und knochenseitig ganz oder teilweise resorbierbarer matrix
GB8422876D0 (en) 1984-09-11 1984-10-17 Secr Defence Silicon implant devices
US4608048A (en) 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US5057082A (en) 1988-11-04 1991-10-15 Plastic Injectors, Inc. Trocar assembly
DK0463061T3 (da) 1989-03-17 1993-07-12 Pitman Moore Inc Controlled-release tilførselsindretning til afgivelse af makromolekylære proteiner
US5167625A (en) 1990-10-09 1992-12-01 Sarcos Group Multiple vesicle implantable drug delivery system
AU665067B2 (en) * 1992-04-30 1995-12-14 Takeda Pharmaceutical Company Limited Prefilled syringe
US5366454A (en) 1993-03-17 1994-11-22 La Corporation De L'ecole Polytechnique Implantable medication dispensing device
US5370630A (en) 1993-11-12 1994-12-06 Smidebush; Michael J. Device for injection of fluidic materials into body tissue
US5489266A (en) * 1994-01-25 1996-02-06 Becton, Dickinson And Company Syringe assembly and method for lyophilizing and reconstituting injectable medication
US5558071A (en) 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5591453A (en) 1994-07-27 1997-01-07 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5817327A (en) 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5665114A (en) 1994-08-12 1997-09-09 Meadox Medicals, Inc. Tubular expanded polytetrafluoroethylene implantable prostheses
US5792099A (en) 1995-02-14 1998-08-11 Decamp; Dennis Syringe and cannula for insertion of viscoelastic material into an eye and method of using same
MX9707585A (es) 1995-04-03 1997-12-31 Abbott Lab Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
US6096344A (en) 1995-07-28 2000-08-01 Advanced Polymer Systems, Inc. Bioerodible porous compositions
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
DE19608423A1 (de) 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
FR2749169B1 (fr) * 1996-06-04 1998-08-21 Delab Procede pour constituer une preparation injectable et dispositif pour la mise en oeuvre de ce procede
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5922299A (en) 1996-11-26 1999-07-13 Battelle Memorial Institute Mesoporous-silica films, fibers, and powders by evaporation
JP3217286B2 (ja) * 1996-12-19 2001-10-09 科学技術振興事業団 Ｄｎａ固定化複合体
AU2460099A (en) 1998-01-20 1999-08-02 Drexel University Mesoporous materials and methods of making the same
US6696258B1 (en) 1998-01-20 2004-02-24 Drexel University Mesoporous materials and methods of making the same
US6060036A (en) 1998-02-09 2000-05-09 Implant Sciences Corporation Radioactive seed implants
GB9808052D0 (en) * 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
GB9815819D0 (en) 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
EP1140027B1 (en) 1998-12-23 2005-10-12 Alza Corporation Dosage forms comprising porous particles
JP2002534139A (ja) * 1999-01-05 2002-10-15 マサチューセッツ・アイ・アンド・イア・インファーマリー 網膜と脈絡膜への経強膜徐放性薬剤標的送達
HK1042051A1 (zh) 1999-08-16 2002-08-02 Henceforth Hibernia Inc. 包含有催化生物拟态固形物的治疗及预防用药物，以及其制备和使用方法
GB9924334D0 (en) 1999-10-15 1999-12-15 Secr Defence Pharmaceutical products and methods of fabrication therefor
NZ518311A (en) * 1999-10-18 2003-10-31 Ferx Inc Magnetic targeted carrier composed of iron and ceramic porous materials for the targeted delivery of biologically active agents
SE9903958D0 (sv) 1999-11-02 1999-11-02 Boerje Sellergren Porous materials for selective binding or transport of molecular guests
US6521284B1 (en) 1999-11-03 2003-02-18 Scimed Life Systems, Inc. Process for impregnating a porous material with a cross-linkable composition
AUPQ573300A0 (en) 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
BR0108728A (pt) 2000-02-28 2003-12-30 Aventis Pharma Sa Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
MXPA02009031A (es) 2000-03-14 2004-08-19 Amylin Pharmaceuticals Inc Efectos del peptido-1(7-36) tipo glucagon en la motilidad antro-piloro.duodenal.
GB0008494D0 (en) * 2000-04-07 2000-05-24 Secr Defence Microprojectile delivery system
GB2365769A (en) 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
GB0104383D0 (en) 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
US6973718B2 (en) 2001-05-30 2005-12-13 Microchips, Inc. Methods for conformal coating and sealing microchip reservoir devices
WO2004018360A1 (en) 2002-08-23 2004-03-04 Mcmaster University Methods and compounds for controlling the morphology and shrinkage of silica derived from polyol-modified silanes
KR20050047118A (ko) 2002-09-18 2005-05-19 알러간, 인코포레이티드 안과 임플란트의 수송을 위한 방법 및 장치
WO2004071949A2 (en) 2003-02-13 2004-08-26 The Regents Of The University Of California Nanostructured casting of organic and bio-polymers in porous silicon templates
US7433811B2 (en) 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
SI1677828T1 (sl) 2003-10-21 2013-04-30 Psimedica Limited Kompozitni material, ki vsebuje porozen polprevodnik impregniran z organsko substanco
GB0324483D0 (en) * 2003-10-21 2003-11-19 Psi Medica Ltd Composite material
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
WO2006034042A2 (en) 2004-09-17 2006-03-30 Ormco Corporation Medical treatment apparatus and needle manufacturing method
WO2006039333A1 (en) 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Ophthalmic drug release device for multiple drug release
CA2583054A1 (en) * 2004-10-05 2006-04-13 The University Of Melbourne Porous polyelectrolyte materials
EP1817003B1 (en) 2004-10-29 2018-02-21 The Regents of The University of California Porous silicon microparticles for drug delivery to the eye
JP4977475B2 (ja) 2004-12-21 2012-07-18 日本電気株式会社 フィルム外装電気デバイス用ケース
JP2007091716A (ja) 2005-08-29 2007-04-12 Kuraray Co Ltd 水中薬剤徐放性微粒子及びその製造方法
GB0526332D0 (en) 2005-12-23 2006-02-01 Psimedica Ltd Pharmaceutical product
JP2009529888A (ja) 2006-03-14 2009-08-27 ユニバーシティ オブ ロチェスター 超薄多孔質メンブレンを有する細胞培養装置およびその使用
EP2004172B1 (en) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
JP4984644B2 (ja) * 2006-05-19 2012-07-25 株式会社ジェイ・エム・エス 注射装置
US9248121B2 (en) * 2006-08-21 2016-02-02 Abbott Laboratories Medical devices for controlled drug release
BRPI0717171B1 (pt) 2006-09-25 2023-10-17 Archer Daniels Midland Company Material superabsorvente
JP5141948B2 (ja) * 2007-07-09 2013-02-13 株式会社豊田中央研究所 バイモダルな細孔構造を有する球状シリカ系メソ多孔体及びその製造方法
CN101815504B (zh) * 2007-07-10 2013-11-20 加利福尼亚大学董事会 用于向所选择组织递送组合物的材料和方法
US20130084243A1 (en) 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
GB0817938D0 (en) 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Cosmetic formulations
GB0817936D0 (en) * 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Porous materials
JP5369725B2 (ja) 2009-01-30 2013-12-18 株式会社ニコン 撮像装置
WO2010090596A1 (en) 2009-02-04 2010-08-12 Agency For Science, Technology And Research Hollow silica particle with a polymer thereon
WO2010096733A2 (en) 2009-02-20 2010-08-26 The Regents Of The University Of California Luminescent porous silicon nanoparticles, methods of making and using same
US20100247607A1 (en) 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
JP5382700B2 (ja) * 2009-03-27 2014-01-08 独立行政法人産業技術総合研究所 ロッド状多孔質シリカ粒子
US9023896B2 (en) 2009-05-04 2015-05-05 Psivida Us, Inc. Porous silicon drug-eluting particles
US20110028412A1 (en) 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
DE102010008982A1 (de) 2010-02-24 2011-08-25 Bayer Innovation GmbH, 40225 Siliciumhaltiges, biologisch degradierbares Material zur anti-inflammatorischen Therapie
GB201017048D0 (en) 2010-10-08 2010-11-24 Ucl Business Plc Composition
CN103282020B (zh) 2010-11-01 2016-10-26 普西维达公司 用于递送治疗剂的可生物侵蚀的硅基装置
US20120238994A1 (en) 2010-12-22 2012-09-20 Martin Nazzaro Two-piece injectable drug delivery device with heat-cured seal
CN103402582A (zh) 2011-02-11 2013-11-20 普西维达公司 使用抗水肿疗法治疗黄斑水肿的方法
EP2691115A1 (en) 2011-03-31 2014-02-05 Galderma Research & Development Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014165108A1 (en) 2013-03-12 2014-10-09 Psivida Us, Inc. Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Also Published As

Publication number Publication date
HK1210048A1 (en) 2016-04-15
RU2640918C2 (ru) 2018-01-12
AU2011323524A1 (en) 2013-05-23
CN103282020B (zh) 2016-10-26
AU2016259330B2 (en) 2018-11-08
US11026885B2 (en) 2021-06-08
US20160243276A1 (en) 2016-08-25
US9808421B2 (en) 2017-11-07
JP2013541562A (ja) 2013-11-14
EP2635255B1 (en) 2019-08-21
JP2016121173A (ja) 2016-07-07
TWI615150B (zh) 2018-02-21
US20170035690A1 (en) 2017-02-09
CN104586742A (zh) 2015-05-06
EP2635255A4 (en) 2016-11-09
AU2016259330A1 (en) 2016-12-08
CN104622789A (zh) 2015-05-20
HK1210415A1 (en) 2016-04-22
CN103282020A (zh) 2013-09-04
US20120177695A1 (en) 2012-07-12
CN104622790A (zh) 2015-05-20
IN2013MN00758A (https=) 2015-06-12
HK1210416A1 (en) 2016-04-22
CA2816576A1 (en) 2012-05-10
AU2011323524B2 (en) 2016-12-08
CA2816576C (en) 2020-06-02
RU2013119438A (ru) 2014-12-10
JP6189460B2 (ja) 2017-08-30
WO2012061377A1 (en) 2012-05-10
EP2635255A1 (en) 2013-09-11
US9333173B2 (en) 2016-05-10
TW201306867A (zh) 2013-02-16

Similar Documents

Publication Publication Date Title
JP6189460B2 (ja) 治療薬送達のための生物浸食性ケイ素ベースのデバイス
US9980911B2 (en) Bioerodible silicon-based compositions for delivery of therapeutic agents
US20160346211A1 (en) Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
HK1188733A (en) Bioerodible silicon-based devices for delivery of therapeutic agents
HK1188733B (en) Bioerodible silicon-based devices for delivery of therapeutic agents
US20160075776A1 (en) Compositions and Methods for Controlled Release of Agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150630

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20150902

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161012

R150 Certificate of patent or registration of utility model

Ref document number: 6026424

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees